Ovid Therapeutics Inc. (1OT.F)

2,8400 +0,0800 (+2,90%) Börsenschluss: 01:30PM CEST

Ovid Therapeutics Inc.

41 Ninth Avenue
14th Floor
New York, NY 10001
United States
646 661 7661
https://www.ovidrx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 40

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir	President, CEO & Chairman	958,16k	N/A	1953
Mr. Jeffrey A. Rona	Chief Business and Financial Officer	708,13k	N/A	1968
Mr. Thomas Michael Perone J.D., M.B.A.	General Counsel, Chief Compliance Officer & Corporate Secretary	693,68k	N/A	1965
Mr. Jason Tardio M.B.A.	Chief Operating Officer	607,29k	N/A	1977
Mr. Simon D. Kelner	Chief Human Resources Officer	N/A	N/A	1974
Dr. Dirk Haasner	Senior Vice President of Global Manufacturing & CMC QA	387,86k	N/A	1965
Dr. Todd F. Baumgartner M.D., M.P.H.	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A
Dr. Julia Tsai Ph.D.	Senior Vice President of Clinical Development	N/A	N/A	1975
Ms. Meg Alexander	Chief Strategy Officer	N/A	N/A	N/A
Dr. Manoj Malhotra M.D.	Chief Medical Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Corporate Governance

Ovid Therapeutics Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 8. Die grundlegenden Scores sind Audit: 8, Vorstand: 8, Shareholderrechte: 7, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.